🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 25 of 55

  1. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  2. INAVOLISIB, FULVESTRANT, INAVOLISIB

    Hoffmann-La Roche

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  3. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  4. INAVOLISIB, RO 743-5846/F04, RO7223619, INAVOLISIB, RO 743-5846/F07, Ipatasertib, Rozlytrek 200 mg hard capsules, Alecensa 150 mg hard capsules, Rozlytrek 100 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, INAVOLISIB, Rozlytrek, Ipatasertib, Camonsertib, INAVOLISIB, RO 749-9790/F02-02

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  5. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  6. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  7. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. INC280, INC280, JNJ-61186372

    Janssen-Cilag International N.V.

    Unresectable Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. INCB099280, Adagrasib

    Incyte

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial

  10. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  11. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  12. INFLIXIMAB, DS-8201a, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, PERTUZUMAB

    AstraZeneca AB

    HER2-positive Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  13. INFLIXIMAB, FOLINIC ACID, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, CALCIUM FOLINATE, MYCOPHENOLATE MOFETIL, volrustomig, FLUOROURACIL, BEVACIZUMAB

    AstraZeneca AB

    ​​Colorectal cancer​

    phase 2 small molecule active

    1 trial

  14. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Cancer

    phase 2 mab completed

    1 trial

  15. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Cervical Cancer

    phase 2 mab completed

    1 trial

  16. INO-3112 vaccine

    INOVIO PHARMACEUTICALS, INC.

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  17. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  18. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  19. INXN-2001

    Alaunos Therapeutics

    Melanoma

    phase 2 mab completed

    1 trial

  20. IO102-IO103

    IO Biotech

    Melanoma

    phase 2 small molecule active

    2 trials

  21. IO102-IO103 in combination with pembrolizumab

    IO Biotech

    Lung Cancer Non Small Cell

    phase 2 small molecule completed

    1 trial

  22. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO Biotech

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  23. IONIS-STAT3Rx

    IONIS PHARMACEUTICALS INC

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  24. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  25. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  26. IPH6501

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  27. IPILIMUMAB, AXITINIB, PF-08634404, AXITINIB

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  28. IPILIMUMAB, NIVOLUMAB

    Ningbo Cancer Hospital

    type B3 thymoma and thymic carcinoma

    phase 2 small molecule active

    1 trial

  29. IPN01203

    Ipsen

    Advanced Solid Tumor, Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  30. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  31. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  32. IRINOTECAN, lurbinectedin

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  33. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  34. ISIS 2503

    IONIS PHARMACEUTICALS INC

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  35. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  36. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Castrate-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  37. IXAZOMIB

    Takeda

    Follicular Lymphoma

    phase 2 small molecule completed

    1 trial

  38. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  39. Ibrutinib 560 mg

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  40. Iclusig 15 mg film-coated tablets

    Ningbo Cancer Hospital

    Chronic myelogenous leukemia

    phase 2 small molecule active

    1 trial

  41. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  42. Iclusig 15 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Ponatinib, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 30 mg film-coated tablets., Ponatinib, Iclusig 45 mg film-coated tablets, Ponatinib

    Incyte

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial

  43. Iclusig 30 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Ponatinib

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  44. Icotinib

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  45. Icotinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. Idasanutlin

    Hoffmann-La Roche

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  47. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Malignant Solid Tumor

    phase 2 small molecule active

    1 trial

  48. Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.